Therapeutic angiogenesis in cardiovascular disease

[1]  J. Hartikainen,et al.  Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT) , 2003, Circulation.

[2]  Shahin Rafii,et al.  Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration , 2003, Nature Medicine.

[3]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[4]  M. Simons,et al.  Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. , 2003, Journal of applied physiology.

[5]  M. Simons,et al.  Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. , 2003, Trends in cardiovascular medicine.

[6]  M. Voskuil,et al.  Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. , 2003, American Journal of Physiology. Heart and Circulatory Physiology.

[7]  Philippe Leboulch,et al.  Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.

[8]  Brian H Annex,et al.  The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .

[9]  R. Hajjar,et al.  Decreased Efficiency of Adenovirus-Mediated Gene Transfer in Aging Cardiomyocytes , 2003, Circulation.

[10]  W. Schaper,et al.  Arteriogenesis: the development and growth of collateral arteries. , 2003, Microcirculation.

[11]  Bernd Westphal,et al.  Autologous bone-marrow stem-cell transplantation for myocardial regeneration , 2003, The Lancet.

[12]  Hung-Fat Tse,et al.  Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation , 2003, The Lancet.

[13]  W. Schaper,et al.  Blood monocyte concentration is critical for enhancement of collateral artery growth. , 2002, American journal of physiology. Heart and circulatory physiology.

[14]  Moon-Kyoung Bae,et al.  Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation , 2002, Cell.

[15]  J. Ware,et al.  Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. , 2002, The Journal of thoracic and cardiovascular surgery.

[16]  R. Lederman,et al.  Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.

[17]  D. Warltier,et al.  Angiostatin Inhibits Coronary Angiogenesis During Impaired Production of Nitric Oxide , 2002, Circulation.

[18]  Jian Li,et al.  Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1alpha-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. , 2002, Journal of cell science.

[19]  R. Hendel,et al.  Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia , 2002, Circulation.

[20]  P. Carmeliet,et al.  Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.

[21]  E. Scott,et al.  Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion , 2002, Nature.

[22]  Qi-Long Ying,et al.  Changing potency by spontaneous fusion , 2002, Nature.

[23]  C. Grines,et al.  Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris , 2002, Circulation.

[24]  Robert J Lederman,et al.  Incomplete retention after direct myocardial injection , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[25]  T. Henry,et al.  Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.

[26]  M. Goldberg,et al.  Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1α , 2002 .

[27]  D. Latchman,et al.  In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo , 2001, Gene Therapy.

[28]  M. Moses,et al.  HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. , 2001, Cancer research.

[29]  M. Simons,et al.  Therapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi? , 2001, American journal of physiology. Heart and circulatory physiology.

[30]  N. Weissman,et al.  Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. , 2001, Journal of the American College of Cardiology.

[31]  Andrew D. Miller,et al.  In vivo myocardial gene transfer: Optimization, evaluation and direct comparison of gene transfer vectors , 2001, Basic Research in Cardiology.

[32]  S. Homma,et al.  Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function , 2001, Nature Medicine.

[33]  F. Sellke,et al.  Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.

[34]  R. B. Johnson,et al.  Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. , 2001, Journal of the American College of Cardiology.

[35]  G. Franklin,et al.  The Sequential Activation and Repression of the Human PDGF-B Gene During Chronic Hypoxia Reveals Antagonistic Roles for the Depletion of Oxygen and Glucose , 2001, Growth factors.

[36]  R O Bonow,et al.  Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. , 2000, Circulation.

[37]  T. Ogihara,et al.  Novel molecular therapeutic approach to cardiovascular disease based on hepatocyte growth factor. , 2000, Journal of atherosclerosis and thrombosis.

[38]  M. Goldberg,et al.  Angiogenesis Is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1&agr;/VP16 Hybrid Transcription Factor , 2000, Circulation.

[39]  Keelan,et al.  The Coronary Venous System: An Alternate Portal to the Myocardium for Diagnostic and Therapeutic Procedures in Invasive Cardiology. , 2000, Current interventional cardiology reports.

[40]  E. Levin,et al.  Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing , 1999, Nature Medicine.

[41]  S. Mudaliar,et al.  Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise. , 1999, American journal of physiology. Heart and circulatory physiology.

[42]  J. Pearlman,et al.  Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. , 1999, Circulation.

[43]  K. Seibert,et al.  COX‐2 Inhibitors: A New Class of Antiangiogenic Agents , 1999, Annals of the New York Academy of Sciences.

[44]  P Lavie,et al.  Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. , 1999, Circulation.

[45]  F. Sellke,et al.  Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[46]  D. Zipes,et al.  Efficient in vivo catheter‐based pericardial gene transfer mediated by adenoviral vectors , 1999, Clinical cardiology.

[47]  J. Spertus,et al.  Comparison of three quality of life instruments in stable angina pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF-36), and Quality of Life Index-Cardiac Version III. , 1998, Journal of Clinical Epidemiology.

[48]  F. Sellke,et al.  Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. , 1997, The American journal of physiology.

[49]  W. Schaper,et al.  Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. , 1997, Circulation research.

[50]  J. Ware,et al.  Angiogenesis in ischemic heart disease , 1997, Nature Medicine.

[51]  W. Schaper,et al.  Molecular mechanisms of coronary collateral vessel growth. , 1996, Circulation research.

[52]  J. Pearlman,et al.  Vascular endothelial growth factor administration in chronic myocardial ischemia. , 1996, The American journal of physiology.

[53]  S. Signoretti,et al.  Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. , 1996, Gene therapy.

[54]  M. Voskuil,et al.  Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. , 2003, Cardiovascular research.

[55]  A. Luttun,et al.  Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.

[56]  J. Michel,et al.  Increasing endothelial cell permeability improves the efficiency of myocyte adenoviral vector infection , 2001, The journal of gene medicine.

[57]  P. Carmeliet,et al.  PR39, a peptide regulator of angiogenesis , 2000, Nature Medicine.

[58]  W. Schaper,et al.  Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. , 1998, The Journal of clinical investigation.